Challenge Your Exam Readiness With Our Free AOCNP Practice Questions

The benefit of prostate cancer screening accrues slowly and is unlikely to outweigh harms (false positives, biopsies, overdiagnosis, treatment toxicity) when life expectancy is <10 years or significant comorbidity limits curative treatment. For older adults with multimorbidity and no symptoms, discontinuing PSA screening is appropriate. Discuss why—competing mortality risks, slow natural history of many screen-detected cancers—and emphasize prompt evaluation for new symptoms (bone pain, obstructive/hematuria) rather than routine PSA testing. MRI screening (Option C) is not recommended for average-risk asymptomatic men. Extending the interval (Option D) still exposes to low-value testing. Continuing annually (Option A) may lead to cascades of testing without meaningful survival benefit. APRNs should incorporate shared decision-making, deprescribe low-value services, and pivot to interventions with clear benefit: vaccination, tobacco cessation support, fall prevention, BP/lipid/diabetes control, and advance care planning. Document the rationale and communicate with primary care to ensure consistent messaging and avoid fragmented, duplicative testing.